trial · primary record
Ublituximab
Myasthenia Gravis
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 120 |
| Primary completion | 2030-01-01 |
| Primary endpoint | Time to Onset of a Clinical Worsening Event |
| Registry ID | NCT07673744 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:33:02.846Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07673744
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ublituximab · compound